The role of recombinant human DNase in the treatment of patients with cystic fibrosis: Many promises, more problems

Thorax

Volumn 51, Issue 7, 1996, Pages 750-755

  Zach, Maximilian S ^a,b  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE; RECOMBINANT DNASE; UNCLASSIFIED DRUG;

CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 0029945249     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.7.750     Document Type: Review

References (63)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
2. Range SP, Knox AJ. rhDNase in cystic fibrosis. Thorax 1995;50:321-2.
3. Hodson ME, Shah PL. DNase trials in cystic fibrosis. Eur Respir J 1995;8:1786-91.
4. Armstrong JB, White JC. Liquifaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950;ii:739-65.
5. Chernick WS, Barbero FJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959;24:739-45.
6. Potter J, Matthews LW, Lemm J, Spector JS. Composition of pulmonary secretions from patients with and without cystic fibrosis. Am J Dis Child 1960;100:493-5.
7. Matthews LW, Spector S, Lemm J, Potter JL. Studies on pulmonary secretions. I. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963; 88:199-204.
8. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978;33:235-42.
9. Lethem MJ, James SL, Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990;142:1053-8.
10. Lethem MJ, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum, Eur Respir J 1990;3:19-23.
11. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-54.
12. Chernick WS, Barbero GJ, Eichel HJ. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics 1961;27:589-96.
13. Lieberman J. Measurement of sputum viscosity in a coneplate viscometer. Am Rev Respir Dis 1968;97:662-72.
14. Elmes PC, White JC. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax 1953;8:295-300.
15. Salomon A, Herschfus JA, Segal MD. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy 1954; 12:71-9.
16. Spier R, Witebsky K, Paine JR. Aerosolized pancreatic dornase and antibiotics in pulmonary infection. JAMA 1961; 178:878-86.
17. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968;205:312-3.
18. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968;98:597-8.
19. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87: 9188-92.
20. Aitken ML, Burke W, McDonald G. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. Phase 1 study. JAMA 1992;267:1947-51.
21. Hubbard RC, McElvaney NG, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326:812-5.
22. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
23. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic cystic. N Engl J Med 1994;331: 637-42.
24. Bryson HM, Sorkin EM. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994;48:894-904.
25. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995;50:333-8.
26. Shah PJ, Bush A, Canny GJ, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 1995;8:954-8.
27. Shah PL, Scott SF, DeSouza L, Nazir T, Marriott C, Hodson ME. Assessment of two nebuliser systems for rhDNase. Pediatr Pulmonol 1995;Suppl 12:237.
28. Brandt T, Breitenstein S, vonderHardt H, Tümmler B. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax 1995;50:880-2.
29. Shah PL, Scott SF, Knight RA, Marriott C, Hodson ME. The effects of recombinant human DNase I on sputum rheology. Eur Respir J 1995;8(Suppl 19):512s.
30. Puchelle E, Zahm JM, Quemada D. Rheological properties controlling mucociliary frequency and respiratory mucus transport. Biorhcology 1987;24:557-63.
31. King M, Zahm JM, Pierrot D, Vaquez-Girod S, Puchelle E. The role of mucus gel viscosity, spinnability and adhesive properties in clearance by simulated cough. Biorhcology 1984;26:737-45.
32. DeBentzmann SG, Pierrot D, Fuchey C, Zahm JM, Morancais JL, Puchelle E. Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of cystic fibrosis mucus. Eur Respir J 1993;6:1156-61.
33. Zahm JM, deBentzmann SG, Deneuville E, et al. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J 1995;8:381-6.
34. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
35. Oberwaldner B. Theißl B, Rucker A, Zach MS. Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production. Eur Respir J 1991;4:152-8.
36. Laube BL, Auci RM, Shields DE, Christiansen D, Fuchs HJ, Rosenstein BJ. A randomized, placebo-controlled trial of the effect of recombinant human DNase I (rhDNase) on the deposition homogeneity and mucociliary clearance of radioaerosol in patients with cystic fibrosis. Pediatr Pulmonol 1993;Suppl 9;155-6.
37. Zach MS. Lung disease in cystic fibrosis an updated concept. Pediatr Pulmonol 1990;8:188-202.
38. Power C, O'Connor CM, Macfarlane D, O'Mahoney S, Gaffney K, Hayes J, et al. Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150:818-22.
39. Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol 1995;19:1-9.
40. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89:499-502.
41. Davies J, Trindade M, Wallis C, Rosenthal M, Bush A. Audit of the effects of rhDNase in children with cystic fibrosis. Eur Respir J 1995;8(Suppl 19):512s.
42. Wojnarowski C, Eichler J, Frischer T, Storm K, Renner S. Götz M. Rh-DNase therapy in patients with CF: is it possible to predict lung function improvement? Pediatr Pulmonol 1995;Suppl 12:236.
43. Romano L, Calvi A, Gaiero A, et al. Mid-term response to treatment with rhDNase can not be anticipated on the basis of sputum production. Pediatr Pulmonol 1995;Suppl 12:237.
44. Costello C, Hayes J, O'Connor C, Fitzgerald MX. Effect of nebulized recombinant DNase on mediators of inflammation in cystic fibrosis. Am J Respir Crit Care Med 1995;151:A20.
45. Stern M, Caplen NJ, Sorgi F, Huang L, Gruenert DC, Geddes DM, et al. The effect of mucolytic agents on liposome-mediated gene transfer across a cystic fibrosis sputum barrier in vitro. Pediatr Pulmonol 1995;Suppl 12: 222.
46. Potter JL, Mathews LW, Spector S, Lemm J. Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics 1965;36: 714-20.
47. Davis SD, Bruns WT. Effects of sputum from patients with cystic fibrosis on the activity in vitro of five antimicrobial drugs on Pseudomonas aeruginosa. Am Rev Respir Dis 1978;117:176-8.
48. Levy J, Smith AL, Kenny MA, Ramsey B, Schocnknecht FD. Bio activity of gentamycin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983;108:1069-76.
49. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132:761-5.
50. Ramphal R, Lhermitte M, Filhat M, Roussel P. The binding of anti-pseudomonas antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988;22: 483-90.
51. Bataillon V, Lhermitte M, Laffite JJ, Pommery J, Roussel P. The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. J Antimicrob Chemother 1992;29:499-508.
52. Clayton R, Wolfson M, Shaffer T, Shidlow D. Effect of recombinant human DNase and tobramycin on pulmonary, surfactant. Pediatr Pulmonol 1995;Suppl 12:235.
53. Shah PL, Scott S, Knight RA, Hodson ME. Quantitative changes in sputum microbiology following treatment of stable cystic fibrosis patients with aerosolized recombinant human DNase I. Pediatr Pulmonol 1993;Suppl 9:265.
54. Munck A, Mariani P, LeBourgeois M, et al. Follow up of anti pseudomonas precipitins in cystic fibrosis patients treated by aerosolized Rh-DNase. Abstracts of the 20th European Cystic Fibrosis Conference, Brussels, June 1995, P88.
55. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-54.
56. McCubbin MM, Meyer K, Fick RB, Balough K. DNA levels are increased in bronchoalveolar lavage fluid from young cystic fibrosis patients with minimal lung disease. Am J Respir Crit Care Med 1995;151:A19.
57. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63-70.
58. Zach MS, Oberwaldner B. Chest physiotherapy - the mechanical approach to antiinfective therapy in cystic fibrosis. Infection 1987;5:381-4.
59. Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonal 1995;20:78-82.
60. Tomkiewicz RP, DeSanctis GT, Boyd WA, King M. Mucolytic synergism in cystic fibrosis (CF) sputum with combined rhDNase and gelsolin treatment. Am J Respir Crit Care Med 1995;151:A19.
61. Dasgupta B, King M. Mucolytic synergism combining rhDNase and nacystelyn in vitro in cystic fibrosis sputum. Eur Respir J 1995;8(Suppl 19):512s.
62. Tomkiewicz RP, Brown NE, King M. Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995;Suppl 12:236.
63. Böllert FCE, McArthur DA, Greening AP, Innes JA. Targeted introduction of DNase in Scotland. Pediatr Pulmonol 1995;Suppl 12:236.